November 25, 2016 - By Peter Erickson · 0 Comments
The stock of Atrion Corporation (NASDAQ:ATRI) registered an increase of 7.08% in short interest. ATRI’s total short interest was 34,800 shares in November as published by FINRA. Its up 7.08% from 32,500 shares, reported previously. With 6,900 shares average volume, it will take short sellers 5 days to cover their ATRI’s short positions. The short interest to Atrion Corporation’s float is 2.48%. The stock increased 0.47% or $2.25 on November 23, hitting $484.25. Atrion Corporation (NASDAQ:ATRI) has risen 21.98% since April 22, 2016 and is uptrending. It has outperformed by 16.58% the S&P500.
Atrion Corporation is engaged in developing and manufacturing products, primarily for medical applications. The company has a market cap of $899.90 million. The Company’s medical products range from fluid delivery devices to ophthalmic and cardiovascular products. It has a 31.98 P/E ratio. The Company’s fluid delivery products include valves that promote infection control and needle safety.
Insitutional Activity: The institutional sentiment increased to 0.94 in Q2 2016. Its up 0.23, from 0.71 in 2016Q1. The ratio improved, as 6 funds sold all Atrion Corporation shares owned while 49 reduced positions. 11 funds bought stakes while 28 increased positions. They now own 951,213 shares or 2.74% less from 978,001 shares in 2016Q1.
The New York-based Secor Capital Advisors Limited Partnership has invested 0.1% in Atrion Corporation (NASDAQ:ATRI). Legal & General Gp Public Ltd last reported 214 shares in the company. Dimensional Fund Advsrs Ltd Partnership holds 0.01% of its portfolio in Atrion Corporation (NASDAQ:ATRI) for 60,282 shares. Panagora Asset owns 443 shares or 0% of their US portfolio. State Common Retirement Fund owns 1,600 shares or 0% of their US portfolio. Swiss Bank accumulated 2,302 shares or 0% of the stock. D E Shaw & reported 967 shares or 0% of all its holdings. The New York-based Citigroup Incorporated has invested 0% in Atrion Corporation (NASDAQ:ATRI). Martin & Inc Tn owns 3,814 shares or 0.53% of their US portfolio. Barclays Public Limited Co, a United Kingdom-based fund reported 6 shares. Ladenburg Thalmann Fincl Incorporated holds 0% of its portfolio in Atrion Corporation (NASDAQ:ATRI) for 11 shares. Morgan Stanley holds 1,722 shares or 0% of its portfolio. Livingston Group Asset Mgmt Company (Operating As Southport Management) reported 1,000 shares or 0.24% of all its holdings. Renaissance Technologies Limited Liability Company has invested 0.02% of its portfolio in Atrion Corporation (NASDAQ:ATRI). Partners Limited Liability Corporation holds 0.02% or 700 shares in its portfolio.
Insider Transactions: Since June 15, 2016, the stock had 0 buys, and 6 sales for $4.42 million net activity. STEBBING ROGER F sold 784 shares worth $350,164. Shares for $420,856 were sold by BATTAT EMILE A. MORGAN HUGH J JR sold $891,476 worth of stock or 2,021 shares.
Atrion Corporation (Atrion), incorporated on December 30, 1996, is engaged in developing and manufacturing products, primarily for medical applications. The Company’s medical products range from fluid delivery devices to ophthalmic and cardiovascular products. The Company’s fluid delivery products include valves that promote infection control and needle safety. It has developed a range of valves designed to fill, hold and release controlled amounts of fluids or gasses on demand for use in various intubation, intravenous, catheter and other applications in areas, such as anesthesia and oncology.
More news for Atrion Corporation (NASDAQ:ATRI) were recently published by: Seekingalpha.com, which released: “Atrion Corporation: Is It A Worthy Investment For The Long Term?” on March 20, 2015. Seekingalpha.com‘s article titled: “Atrion Corporation: Not Quite A Bargain, But A Company Investors Should Keep …” and published on November 07, 2014 is yet another important article.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Peter Erickson